DE60021583D1 - Arzneimittel für die verhinderung und/oder behandlung von kardialen durchblutungsstörungen, peripheren gefässkrankheiten, tumoren und wunden - Google Patents

Arzneimittel für die verhinderung und/oder behandlung von kardialen durchblutungsstörungen, peripheren gefässkrankheiten, tumoren und wunden

Info

Publication number
DE60021583D1
DE60021583D1 DE60021583T DE60021583T DE60021583D1 DE 60021583 D1 DE60021583 D1 DE 60021583D1 DE 60021583 T DE60021583 T DE 60021583T DE 60021583 T DE60021583 T DE 60021583T DE 60021583 D1 DE60021583 D1 DE 60021583D1
Authority
DE
Germany
Prior art keywords
diseases
peripheral vascular
cardial
wounds
bleaching
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60021583T
Other languages
English (en)
Inventor
Jean-Luc Balligand
Olivier Feron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Catholique de Louvain UCL
Original Assignee
Universite Catholique de Louvain UCL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Catholique de Louvain UCL filed Critical Universite Catholique de Louvain UCL
Application granted granted Critical
Publication of DE60021583D1 publication Critical patent/DE60021583D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60021583T 1999-08-09 2000-08-09 Arzneimittel für die verhinderung und/oder behandlung von kardialen durchblutungsstörungen, peripheren gefässkrankheiten, tumoren und wunden Expired - Fee Related DE60021583D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99870171A EP1076091A1 (de) 1999-08-09 1999-08-09 Arzneimittel für die Verhinderung und/oder Behandlung von Herzischämie, peripheren Gefässkrankheiten, Tumoren und Wunden
PCT/EP2000/007731 WO2001011038A2 (de) 1999-08-09 2000-08-09 Use

Publications (1)

Publication Number Publication Date
DE60021583D1 true DE60021583D1 (de) 2005-09-01

Family

ID=8243881

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60021583T Expired - Fee Related DE60021583D1 (de) 1999-08-09 2000-08-09 Arzneimittel für die verhinderung und/oder behandlung von kardialen durchblutungsstörungen, peripheren gefässkrankheiten, tumoren und wunden

Country Status (6)

Country Link
US (1) US20020156123A1 (de)
EP (3) EP1076091A1 (de)
AT (1) ATE300614T1 (de)
AU (1) AU6440800A (de)
DE (1) DE60021583D1 (de)
WO (1) WO2001011038A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001024826A2 (en) * 1999-10-06 2001-04-12 The Brigham And Women's Hospital, Inc. Inrease of enos activity through activation of the pi3-kinase/akt pathway by estrogens
GB2360453B (en) * 2000-01-05 2004-09-01 Univ Cardiff Treatment of skin conditions
US20020077283A1 (en) 2000-09-08 2002-06-20 Sessa William C. Caveolin peptides and their use as therapeutics
AU2002951611A0 (en) * 2002-09-24 2002-10-10 The Baker Medical Research Institute Cholesterol efflux and uses thereof
WO2009116695A1 (en) * 2008-03-21 2009-09-24 Seoul National University Industry Foundation A composition for treatment and improvement of diabetes comprising caveolin as active ingredient and a method for treatment of diabetes using it
US20150141340A1 (en) * 2012-06-04 2015-05-21 Yale University Method of treating and preventing ocular angiogenesis
ES2875853T3 (es) 2013-03-15 2021-11-11 Univ Texas Método de tratar fibrosis
AU2019339260A1 (en) 2018-09-10 2021-03-25 Lung Therapeutics, Inc. Modified peptide fragments of Cav-1 protein and the use thereof in the treatment of fibrosis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244908A (en) * 1990-07-30 1993-09-14 Takeda Chemical Industries, Ltd. Imidazopyridine derivatives and their pharmaceutical use
FR2722507B1 (fr) * 1994-07-12 1996-08-14 Rhone Poulenc Rorer Sa Adenovirus comportant un gene codant pour une no synthase
JPH1087698A (ja) * 1996-07-09 1998-04-07 Takeda Chem Ind Ltd 新規タンパク質およびそのｄｎａ
WO1998048826A1 (en) * 1997-04-30 1998-11-05 Northwestern University Inhibition of nitric oxide synthase by amino acids and dipeptides
CN1117566C (zh) * 1997-08-29 2003-08-13 辉瑞产品公司 包含氨氯地平和抑制素化合物的联合药物形式
US6007821A (en) * 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
CA2308565A1 (en) * 1997-11-05 1999-05-14 Baylor College Of Medicine Sequences for targeting metastatic cells
WO1999030706A1 (en) * 1997-12-12 1999-06-24 Warner-Lambert Company ANTIHYPERLIPIDEMIC STATIN-LP(a) INHIBITOR COMBINATIONS
WO1999046592A1 (en) * 1998-03-09 1999-09-16 The Regents Of The University Of California Regulation of the cell cycle by sterols
AU4988100A (en) * 1999-05-07 2000-11-21 Brigham And Women's Hospital Use of hmgcoa reductase inhibitors in the prevention of diseases whose pathogenesis is dependent on neovascularization

Also Published As

Publication number Publication date
EP1206539B1 (de) 2005-07-27
WO2001011038A3 (de) 2001-12-13
EP1586644A2 (de) 2005-10-19
WO2001011038A2 (de) 2001-02-15
EP1076091A1 (de) 2001-02-14
US20020156123A1 (en) 2002-10-24
EP1586644A3 (de) 2008-06-25
AU6440800A (en) 2001-03-05
ATE300614T1 (de) 2005-08-15
EP1206539A2 (de) 2002-05-22

Similar Documents

Publication Publication Date Title
ATE339187T1 (de) Verwendung von zusammensetzungen mit antiseptika und/oder die wundheilung fördernden wirkstoffen für den tieferen atemwegstrakt
BR0209523A (pt) Utilização de um antioxidante para a fabricação de um medicamento destinado ao tratamento e/ou à prevenção dos distúrbios oculares de superfìcie
ES2054995T3 (es) Nuevos derivados del acido benzoico y acido fenilacetico, su obtencion y empleo como medicamentos.
IS2114B (is) Kínasólínafleiður til að meðhöndla æxli
HUP9902105A2 (hu) Angiosztatikus dipeptideket tartalmazó gyógyászati készítmények és ezek alkalmazása
DE3382641D1 (de) Arzneimittel fuer die therapeutische behandlung von alopezie.
DE69634556D1 (de) L-Carnitin oder ihre Derivate und Resveratrol oder ihre Derivate zur Vorbeugung und Behandlung von kardiovaskulären Erkrankungen, peripheren Gefässkrankheit, peripheren diabetischen Neuropathie und diese enthaltende pharmazeutische Zusammensetzungen
DE69715439T2 (de) Pyridylalkan-säureamide als cytostatika und immunosupressive arzneimittel
ATE203403T1 (de) Verwendung von prolin als einziger therapeutischer wirkstoff zur herstellung eines arzneimittels zur behandlung von rheumatischen erkrankungen und von chronischen und traumatisch bedingten schmerzzuständen
ATE145136T1 (de) Verwendung von ketoconazol und ein retinoid zur behandlung der akne vulgaris
BR9707153A (pt) Compostos biaromáticos composição farmacêutica composição cosmética e utilização de uma composição cosmética
ATE231852T1 (de) Bicyclische aromatische verbindungen
DE69713620D1 (de) Verwendung von arachidonsäure und/oder docohexaensäure zur herstellung eines arzneimittels zur behandlung von dyspraxia
NZ328874A (en) Heterocyclic biaryl compounds and their use in pharmaceutical compositions for treatment of dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders
ATE198550T1 (de) Verwendung von weihrauch zur behandlung der alzheimer-krankheit
DE60021583D1 (de) Arzneimittel für die verhinderung und/oder behandlung von kardialen durchblutungsstörungen, peripheren gefässkrankheiten, tumoren und wunden
BR9910899A (pt) Compostos de ácido sulfÈnico ou sulfonilamino n-(hetero-aralquil)-azaeterocicliamida
MX9501849A (es) Nuevos compuestos biciclicos-aromaticos, composiciones farmaceuticas y cosmeticas que los contienen y sus usos.
ATE289805T1 (de) Verwendung von antiseptika zur herstelllung von arzneimitteln zur prophylaxe und behandlung von infektionen und/ oder funktionellen gewebeumformungen im körperinneren
DE60115054D1 (de) Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs
FR2713640B1 (fr) Nouveaux composés aromatiques polycycliques, compositions pharmaceutiques et cosmétiques les contenant et utilisations.
ATE266027T1 (de) Optisch aktives pyridyl-4h-1,2,4-oxadiazinderivat und seine verwendung zur behandlung von gefässkrankheiten
WO1999050239A3 (fr) Nouveaux composes heteroethynylenes et compositions pharmaceutiques et cosmetiques les contenant
DE68905076T2 (de) Pharmazeutische Zusammensetzung für die Behandlung von Hautwunden.
ATE331523T1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee